# The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

> **NCT01826786** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 43 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42165279 (100 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01826786
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826786, "The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01826786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*